Advert - Daiichi-Sankyo

Disclosure of payments on Disclosure UK

For failing to have adequate processes in place to correctly
disclose transfers of value in relation to support to health
professionals to attend conferences in 2018, 2017 and 2016,
Daiichi-Sankyo was ruled in breach of the following clauses of
the Code:

Clause 2 - Bringing discredit upon, and reducing confidence
in, the pharmaceutical industry

Clause 9.1 - Failing to maintain high standards

Clause 22.5 - Failing to publicly disclose financial details of
sponsorship of health professionals in relation to
attendance at meetings

Clause 24.1 - Failing to document and publicly disclose certain
transfers of value to health professionals

Clause 24.4 - Failing to disclose transfers of value annually
within the first six months after the end of the
calendar year in which the transfers of value
were made

Clause 24.6 - Failing to document all disclosures and retain the
records for at least five years after the end of the
calendar year to which they relate

Clause 24.7 - Failing to aggregate by category and have
available itemised transfers of value to individual
health professionals

Clause 24.9 - Failing to disclose transfers of values on an
aggregate basis when unable to disclose on an
individual basis

In addition, the Code of Practice Appeal Board required Daiichi-Sankyo to be publicly reprimanded for its fundamental systemic failure to have adequate processes in place to correctly disclose transfers of value over a three-year period; the company was also required to be audited.

Advert September 2020